﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: All</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "All"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365177v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365110v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365161v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365106v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365118v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.08.26365057v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26363506v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26365208v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26365195v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26365202v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365120v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365165v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26365209v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26364958v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26365226v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26364870v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26365211v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365112v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26364862v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365056v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365109v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26364997v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365189v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365176v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365170v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365115v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365178v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365132v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.09.26365168v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.10.10.26364993v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365177v1?rss=1">
<title>
<![CDATA[
Atrial fibrillation begets atrial fibrillation - serum-driven amplification of atrial electrical instability 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365177v1?rss=1
</link>
<description><![CDATA[
Rationale: Atrial fibrillation (AF) is sustained by electrical triggers and atrial substrate, but whether AF itself generates circulating factors that acutely reinforce arrhythmogenesis is unknown. Objective: To determine whether rhythm-dependent serum bioactivity directly destabilizes atrial electrophysiology and to identify associated cellular mechanisms and circulating mediators. Methods and Results: Cardiac samples were obtained from patients with persistent atrial fibrillation (AF) during AF and after restoration of sinus rhythm (SR) using electrical cardioversion. In isolated Langendorff-perfused mouse hearts, AF serum increased the duration, frequency, and cumulative burden of spontaneous atrial depolarizations compared with paired control perfusate. In human induced pluripotent stem cell derived atrial cardiomyocytes, AF patient serum decreased Ca2-transient amplitudes without significant effect on kinetics or Ca2 spark activity. Moreover, AF serum reduced peak sodium current without materially altering voltage-dependent gating or paced action-potential properties. Data-independent acquisition proteomics identified rhythm-associated changes in extracellular-matrix, proteolytic, inflammatory, and signaling proteins, including MMP9, Ccathepsin G, and 14-3-3 family members. Targeted pathway perturbation differentially modified serum-induced Ca2 phenotypes, indicating context-dependent, multifactorial bioactivity. Serum-induced Ca2 responses were not associated with indices of atrial disease severity, including low-voltage substrate burden and left atrial pressure. Conclusions: Persistent AF is accompanied by rhythm-dependent circulating bioactivity that acutely promotes atrial electrical instability and Ca2-dependent trigger formation. These findings extend the concept that AF begets AF beyond tissue-intrinsic remodeling and identify a potentially reversible serum-mediated feed-forward mechanism linking rhythm status and circulating proteomic signals in an atrial substrate severity independent fashion. Keywords: atrial fibrillation; serum; atrial cardiomyopathy; calcium signaling; circulating factors; proteomics
]]></description>
<dc:creator><![CDATA[ Bögner, M., Ramesh, G., Fahjen, P., Hüttemeister, J., Kirk, M., Heil, E., Bock, M., Zhang, K., Boehm, G., Eichelmann, L., Gerds-Li, J. H., Hilgendorf, I., Falk, V., Mertins, P., Hindricks, G., Hohendanner, F. ]]></dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365177</dc:identifier>
<dc:title><![CDATA[Atrial fibrillation begets atrial fibrillation - serum-driven amplification of atrial electrical instability]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365110v1?rss=1">
<title>
<![CDATA[
Vascular Remodelling in Idiopathic Nephrotic Syndrome with Administration of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365110v1?rss=1
</link>
<description><![CDATA[
Background Pediatric nephrotic syndrome (NS) significantly increases cardiovascular risk, primarily through activation of the renin-angiotensin-aldosterone system (RAAS) and chronic inflammation. This study aimed to evaluate the relationship between serum aldosterone and interleukin 6 (IL-6) levels with carotid intima-media thickness (CIMT) in children with steroid-sensitive (SSNS) and steroid-resistant NS (SRNS), both before and after combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). Materials and methods A prospective cohort study enrolled 32 children aged 2-18 years with idiopathic NS at Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia (May-June 2024). Participants received lisinopril (ACEI) or valsartan (ARB) for 12 weeks. Serum aldosterone was quantified via liquid chromatography-tandem mass spectrometry, IL-6 via electrochemiluminescence immunoassay, and CIMT via high-resolution B-mode Doppler ultrasound. Data were analyzed using SPSS version 26.0, including Shapiro Wilk normality testing, Pearson/Spearman correlations, and multivariate linear regression (enter method, R2=0.022), with statistical significance set at p<0.05. Results CIMT decreased significantly post-treatment (0.13{+/-}0.04 cm to 0.06{+/-}0.01 cm; p<0.001). Serum aldosterone remained stable (5.15 to 4.0 ng/dL; p=0.933), as did IL-6 (3.5 pg/mL; p=0.156). Univariate analyses revealed weak correlations (aldosterone-CIMT: R2=0.075; IL-6-CIMT: R2=0.215). Multivariate regression (R2=0.022) identified SRNS as positively associated with CIMT change (p=0.047), while aldosterone and IL-6 showed no significant independent effects. Conclusion This study highlights that ACEI and ARB therapy improved CIMT regardless of steroid sensitivity, suggesting vascular benefits may occur through pathways independent of aldosterone and IL-6 modulation.
]]></description>
<dc:creator><![CDATA[ Dimiati, H., Haris, S., Hasballah, K., Pardede, S. ]]></dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365110</dc:identifier>
<dc:title><![CDATA[Vascular Remodelling in Idiopathic Nephrotic Syndrome with Administration of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365161v1?rss=1">
<title>
<![CDATA[
Association of childhood experiences with wellbeing and flourishing outcomes in Indian adults: Evidence from the India Sample of the Global Flourishing Study (GFS) 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365161v1?rss=1
</link>
<description><![CDATA[
Background: Childhood experiences contribute to health and wellbeing across the life course, yet research from low- and middle-income countries has largely focused on a few outcomes rather than broader patterns of adult wellbeing, behaviors, and social and financial circumstances. Methods: In this cross-sectional analysis, we used a nationally representative sample of adults in India (N = 12,765; aged [&ge;] 18 years) from the Global Flourishing Study (GFS) Wave 1 (2023) to examine associations between eight retrospectively reported childhood experience items, 45 adult outcomes, and two composite flourishing indices. Survey-weighted linear, logistic, and proportional-odds models adjusted for age, gender, education, and residential setting, with Bonferroni correction were used to assess associations and effect modification by gender. Findings: Although the breadth and strength of associations differed across childhood experiences, less favorable childhood experiences were generally associated with poorer wellbeing and flourishing, greater odds of adverse health outcomes, and reduced access to resources and safety in adult life. However, outcomes related to prosocial behaviors showed a different pattern: childhood abuse (physical or sexual) was associated with greater odds of volunteering (OR 1.31, 95% confidence interval or CI [1.13,1.51]), feeling like an outsider in one's family with greater odds of donating (OR 1.80, 95% CI [1.52,2.13]), volunteering (OR 1.53, 95% CI [1.28,1.82]), and helping a stranger (OR 1.49, 95% CI [1.27,1.74]). Associations were broadly similar between females and males, with little evidence of gender differences. Interpretation: Associations of childhood adversity with poorer health and increased prosocial behavior in adult life may reflect unmeasured social, cultural, or dispositional factors and heterogeneous life-course responses. Nevertheless, these findings support strengthening child-protection, financial assistance programs, and mental health services in India.
]]></description>
<dc:creator><![CDATA[ Hou, Y., Sullivan, T., Zang, E., Saxena, S., Gupta, M., Singh, N. C., Mukherjee, B. ]]></dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365161</dc:identifier>
<dc:title><![CDATA[Association of childhood experiences with wellbeing and flourishing outcomes in Indian adults: Evidence from the India Sample of the Global Flourishing Study (GFS)]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365106v1?rss=1">
<title>
<![CDATA[
Language eligibility criteria and enrolled racial and ethnic composition in US clinical trials: a cross-sectional study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365106v1?rss=1
</link>
<description><![CDATA[
BACKGROUND: Federal policy now requires sponsors to submit diversity action plans for clinical trials, yet the modifiable features of trial design associated with enrolled composition remain poorly characterized. English-language proficiency requirements are written into eligibility criteria and recorded as free text in a public registry, making them visible and, in principle, amenable to revision, but their relationship to enrolled composition has been examined only within single disease areas and in small samples of trials. We examined whether these requirements and documented language accommodation were associated with the racial and ethnic composition of enrolled participants. METHODS AND FINDINGS: We conducted a cross-sectional study of interventional trials registered on ClinicalTrials.gov with at least one US site and posted results, using a registry snapshot retrieved in October 2026. The primary cohort comprised the 44,487 trials with exclusively US sites, of which 21,924 (49.3%) reported baseline race and 17,434 (39.2%) reported baseline ethnicity with counts that reconciled with the posted denominator. Both exposures were classified from free-text eligibility criteria using regular expressions validated against independent physician review of 150 trials. For the English-language requirement classifier, sensitivity was 88.2% and specificity was 99.2%. The outcome was the trial-level proportion of enrolled participants in each category, analyzed using generalized linear models adjusted for intervention class, therapeutic area, sponsor, phase, enrollment, sites, start year, US Census region, and the population composition of the trial's site states. An English-language proficiency requirement appeared in 5,736 trials (12.9%); its prevalence rose from 7.4% of trials starting in 2010 to 26.2% in 2023 (odds ratio [OR] per decade 2.91, P<0.001), whereas documented accommodation, an eligibility statement allowing participation in a language other than English (Spanish in 99.9% of flagged trials), remained rare (788 trials, 1.8%). The requirement was associated with lower enrolled proportions of Asian (OR=0.85, 95% CI 0.77-0.93, P=0.001) and Hispanic/Latinx participants (OR=0.85, 95% CI 0.79-0.91, P<0.001), with no evidence of an association for White participants (OR=0.99, 95% CI 0.95-1.04, P=0.75). Documented accommodation was associated with a higher proportion of Hispanic/Latinx participants (OR=3.23, 95% CI 2.82-3.71, P<0.001). Geographic adjustment did not change the statistical significance of the requirement associations and attenuated the accommodation association. The main limitations were the cross-sectional design, which precludes causal inference; the restriction of enrollment analyses to trials reporting baseline demographics, which were more recent than those without such reporting; and possible misclassification of automatically classified exposures. CONCLUSIONS: English-language proficiency requirements became more than three times as common between 2010 and 2023 and were associated with lower enrolled proportions of Asian and Hispanic/Latinx participants. Less common documented language accommodation was associated with a higher enrolled proportion of Hispanic/Latinx participants. Because these criteria are investigator-written and publicly recorded, they may be a tractable target for improving enrollment equity, although whether revising them changes who enrolls requires prospective evaluation
]]></description>
<dc:creator><![CDATA[ Tolas, A., Du, L. Y., Schutz, N., Schmiedmayer, P., O'Sullivan, J. W., Johnson, A., Longenecker, C. K., Sarraju, A., Rodriguez, F., Yang, E., Kim, D. S. ]]></dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365106</dc:identifier>
<dc:title><![CDATA[Language eligibility criteria and enrolled racial and ethnic composition in US clinical trials: a cross-sectional study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365118v1?rss=1">
<title>
<![CDATA[
Food Hygiene and associated factors among street food vendors of selected districts of Bagamati Province, Nepal: A cross-sectional study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365118v1?rss=1
</link>
<description><![CDATA[
Background Street food vending is a major source of food supply in Nepal. Poor food hygiene practices among street food vendors pose a health risk by increasing the risk of foodborne diseases. Studies regarding food hygiene knowledge and practices are needed to improve public awareness. Therefore, this study aimed to assess food hygiene knowledge and practice among street food vendors and their associated factors in selected districts of Bagamati Province. Methods A community-based cross-sectional analytical study was carried out among 186 street food vendors of Districts located in central Nepal. Face-to-face interviews were conducted using a semi-structured questionnaire and an observation checklist. Knowledge and practice levels were categorized as good and poor. Chi-square test, Fisher's exact test, odds ratio, and Mann-Whitney U test were applied for data analysis. Results Less than half (39.8%) of the vendors had good food hygiene knowledge, while 91.4% of the respondents reported good food safety and hygiene practices. The education level of street food vendors was significantly associated with food hygiene knowledge (p = 0.001) and food safety and hygiene practices (p = 0.042). Significant association was not seen between overall food hygiene knowledge and overall food safety and hygiene practices levels. Conclusion The study identified a gap between food hygiene knowledge and self-reported food hygiene practices among street food vendors. Education, infrastructure, and regulations among street food vendors play a key role in good food hygiene practices more than knowledge alone. Policymakers should focus on training of food vendors, regular supervision, and monitoring of vending sites to enhance food safety.
]]></description>
<dc:creator><![CDATA[ Poudel, S., Dahal, A., Nangia, A. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365118</dc:identifier>
<dc:title><![CDATA[Food Hygiene and associated factors among street food vendors of selected districts of Bagamati Province, Nepal: A cross-sectional study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.08.26365057v1?rss=1">
<title>
<![CDATA[
Contrasting Patterns of Cortical Volume Change in First-Episode Schizophrenia-Spectrum Psychosis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.08.26365057v1?rss=1
</link>
<description><![CDATA[
**Importance** Average gray matter volume (GMV) loss in early psychosis may conceal clinically relevant differences in brain change. **Objective** To identify longitudinal GMV-change patterns, their cross-site correspondence, and clinical associations. **Design, Setting, and Participants** Prospective cohort with T1-weighted MRI acquired during 2011-2026 at 2 Czech sites; median follow-up, approximately 13 months. Participants were 222 patients with first-episode schizophrenia-spectrum psychosis and 178 healthy controls frequency-matched by site and baseline age. **Exposure** First-episode psychosis vs healthy control status. **Main Outcomes and Measures** Diagnosis-blind clustering by site of image-quality-corrected, subsequently annualized GMV change across 333 cortical parcels; longitudinal voxel-based morphometry (VBM); Global Assessment of Functioning and consensus 5-factor Positive and Negative Syndrome Scale negative-symptom scores. **Results** Among 400 participants (mean [SD] age, 28.2 [7.5] years), 208 (52.0%) were male. Each site independently yielded 3 clusters: C1 (near-stable GMV), C2 (pronounced decrease), and C3 (increase). Cross-site centroid correlations across 333 parcels were strong for C2 and C3 (Spearman rho = 0.865 and 0.861); C1 correlation was weak (rho = 0.138), as expected for near-zero profiles with little regional variation. C2/C3 correspondence supported pooling matched site-specific clusters for post hoc analyses. Pooled clusters contained 77 patients and 125 controls in C1, 66 patients and 16 controls in C2, and 79 patients and 37 controls in C3. Suffixes -P and -HC identify patient and control subgroups. To situate patient changes relative to controls, post hoc VBM revealed an unanticipated gradient of increasingly pronounced GMV reduction across C1-HC to C1-P to C2-P, prominently involving association cortex, and bilateral ventral temporal GMV increase in C3-P (familywise error-corrected P < .05). The opposite contrast along this ordering showed periventricular changes consistent with progressively greater ventricular enlargement. C2-P had the lowest mean follow-up functioning and highest mean negative-symptom severity (adjusted omnibus P = .005 and .02); clinical changes from baseline did not differ significantly among patient groups. **Conclusions and Relevance** Early GMV change in psychosis was not uniform but comprised two contrasting directions: a clinically relevant, control-anchored pattern of increasingly pronounced GMV loss involving default mode regions and a distinct, directionally opposing ventral temporal increase.
]]></description>
<dc:creator><![CDATA[ Spaniel, F., Skoch, A., Kolenic, M., Tomecek, D., Kawikova, I., Bakstein, E., Hlinka, J., Fialova, M., Jakob, L., Capek, V. ]]></dc:creator>
<dc:date>2026-10-13</dc:date>
<dc:identifier>doi:10.64898/2026.10.08.26365057</dc:identifier>
<dc:title><![CDATA[Contrasting Patterns of Cortical Volume Change in First-Episode Schizophrenia-Spectrum Psychosis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26363506v1?rss=1">
<title>
<![CDATA[
Uneven Recovery of Exercise Training in US Adults With Cardiovascular Risk Factors or Disease Following the COVID 19 Pandemic 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26363506v1?rss=1
</link>
<description><![CDATA[
The COVID-19 pandemic led to significant disruptions in cardiovascular care and reductions in physical activity, but little is known about how exercise patterns changed after this period. This study assessed changes in weekly aerobic and strength training activity between 2020 and 2022 amongst adults aged 18 years or older who reported one or more cardiovascular diseases or risk factors. This study used National Health Interview Survey data from 2020 and 2022. Adjusted differences for moderate-to-vigorous physical activity (MVPA) were calculated using a linear regression model and for strength sessions using a Poisson regression, adjusting for sex and age. Changes in these outcomes were then stratified by age and sex subgroups. The weighted study population included 182,783,008 (standard error, +/-3,334,337) adults in 2020 and 185,388,060 (SE, +/-3,285,161) adults in 2022. Between 2020 and 2022, the overall weekly MVPA increased from 244.2 (SE, +/-4.5) minutes to 266.3 (SE, +/-5.7) minutes (adjusted difference, +22.1 [SE, +/-6.92] minutes). There were no statistically significant changes in the number of strength session per week overall or among sex and age subgroups. Across sex and age subgroups, increases in weekly MVPA were entirely concentrated among males and younger adults. The recovery from pandemic era reductions in aerobic and strength exercise training was uneven amongst demographic subgroups, which aligns with concurrent persistent disruptions in cardiovascular care.
]]></description>
<dc:creator><![CDATA[ Oddleifson, D. A., Zu, J., Wadhera, R. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26363506</dc:identifier>
<dc:title><![CDATA[Uneven Recovery of Exercise Training in US Adults With Cardiovascular Risk Factors or Disease Following the COVID 19 Pandemic]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26365208v1?rss=1">
<title>
<![CDATA[
Efficacy of Disease-Modifying Treatments in Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis of Five Phase III Randomized Controlled Trials 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26365208v1?rss=1
</link>
<description><![CDATA[
Background Several disease-modifying agents for transthyretin amyloid cardiomyopathy (ATTR-CM) have been investigated, but differences in trial design and background stabilizer use complicate interpretation of their efficacy. This meta-analysis assessed their efficacy overall and by background stabilizer use. Methods PubMed, Embase, and the Cochrane Library were searched through September 2026 for phase III randomized, placebo-controlled trials of disease-modifying therapy in ATTR-CM. Primary endpoints were all-cause mortality, 6-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score, and N-terminal pro-B-type natriuretic peptide (NT-proBNP), pooled with a random-effects model. Treatment effects were compared between the monotherapy and baseline stabilizer strata using a mixed-effects model. Results Five trials (ATTR-ACT, APOLLO-B, ATTRibute-CM, HELIOS-B, CARDIO-TTRansform; N=3497) were included. Disease-modifying therapy reduced all-cause mortality (risk ratio, 0.76; 95% confidence interval [CI], 0.66-0.87; I2=0%) and improved 6MWD (pooled standardized mean difference [SMD], 0.43; 95% CI, 0.20-0.67), KCCQ-OS score (SMD, 0.37; 95% CI, 0.19-0.55), and NT-proBNP (SMD, -0.53; 95% CI, -0.89 to -0.18). The mortality benefit was similar whether therapy was given alone or added to a background stabilizer (pooled risk ratio, 0.77 vs. 0.71; P for interaction = 0.59), but treatment effects on 6MWD (pooled SMD, 0.49 vs. 0.14), KCCQ-OS score (0.44 vs. 0.07), and NT-proBNP (-0.65 vs. -0.13) were smaller among patients receiving a background stabilizer (P for interaction = 0.012, <0.001, and 0.029, respectively). Conclusion Disease-modifying treatments reduced all-cause mortality and favored functional capacity, health status, and NT-proBNP outcomes in patients with ATTR-CM. Exploratory subgroup analyses showed smaller treatment effects on 6MWD, KCCQ-OS score, and NT-proBNP among patients receiving a background stabilizer, with no statistically significant difference in the mortality effect according to baseline stabilizer use.
]]></description>
<dc:creator><![CDATA[ Hung, Y.-H., Tsai, C.-H., Kao, T.-W., Wu, Y.-W., Yu, W.-C., Carigi, S., Sperry, B. W., Perlini, S., Lin, Y.-H. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26365208</dc:identifier>
<dc:title><![CDATA[Efficacy of Disease-Modifying Treatments in Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis of Five Phase III Randomized Controlled Trials]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26365195v1?rss=1">
<title>
<![CDATA[
Clinical Effects of Low-Dose Esketamine During Emergency Conversion From Labor Epidural Analgesia to Category I Cesarean Section: A Randomized Controlled Trial of Maternal Hemodynamics, Analgesia, Sedation, and Neonatal Outcomes 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26365195v1?rss=1
</link>
<description><![CDATA[
Background: Emergency conversion from labor epidural analgesia to Category I cesarean section leaves little time for epidural top-up to produce a surgical block. We examined whether low-dose intravenous esketamine could provide short-term bridging analgesia and sedation while maintaining maternal hemodynamics, oxygenation, and early neonatal safety. Methods: In this randomized study, parturients requiring Category I cesarean section after labor epidural analgesia received either esketamine 0.15 mg/kg or normal saline 1 min before skin incision, together with epidural alkalinized lidocaine. The primary outcome was the longitudinal change in maternal systolic blood pressure during the 20-min observation window. Secondary outcomes included heart rate, SpO2, intraoperative pain, surgeon satisfaction with muscle relaxation, Ramsay sedation score, and neonatal Apgar scores. We analyzed repeated continuous outcomes with linear mixed-effects models and repeated binary outcomes with generalized estimating equations. The single post-administration Ramsay outcome was analyzed using logistic regression. Apgar scores were summarized descriptively using medians, interquartile ranges, and counts.Results: We analyzed 55 parturients, 31 in the esketamine group and 24 in the normal saline group. Esketamine did not meaningfully alter the systolic blood pressure trajectory. Heart rate and SpO2 showed broadly similar patterns between groups, with no signal of esketamine-related respiratory deterioration. The esketamine group had lower odds of intraoperative pain at 5, 15, and 20 min and a higher probability of target Ramsay sedation. Surgeon satisfaction with muscle relaxation showed no clear between-group difference. Apgar scores remained high in both groups. Conclusion: Low-dose intravenous esketamine 0.15 mg/kg may be a practical bridging adjunct during emergency conversion from labor epidural analgesia to Category I cesarean section. It improved early pain control and target sedation without a clear adverse signal in systolic blood pressure, heart rate, oxygenation, or early Apgar scores. Trial Registration: Chinese Clinical Trial Registry, ChiCTR2600121948; retrospectively registered.
]]></description>
<dc:creator><![CDATA[ Liang, W., Zhai, L. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26365195</dc:identifier>
<dc:title><![CDATA[Clinical Effects of Low-Dose Esketamine During Emergency Conversion From Labor Epidural Analgesia to Category I Cesarean Section: A Randomized Controlled Trial of Maternal Hemodynamics, Analgesia, Sedation, and Neonatal Outcomes]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26365202v1?rss=1">
<title>
<![CDATA[
Inflammatory protein profiling shows limited ability to distinguish sepsis from sepsis mimics 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26365202v1?rss=1
</link>
<description><![CDATA[
Sepsis mimics resemble sepsis clinically but may require different treatments. We evaluated whether inflammatory protein profiles could distinguish these conditions in a retrospective case-control study using 4 prospective Japanese cohorts. The study included 34 adults with sepsis and 46 with sepsis mimics. We measured 92 proteins using Olink, assessed between-group differences with false discovery rate (FDR) adjustment, and evaluated 3 prediction models using repeated nested cross-validation. No protein met the FDR threshold; the lowest FDR-adjusted P value was 0.345. The primary elastic-net model had an area under the receiver operating characteristic curve of 0.442 (95% confidence interval, 0.315-0.574), based on cross-validation predictions averaged for each participant. Random forest and gradient boosting also showed no clear evidence of discrimination above chance. Confidence intervals included chance performance in both the all-serum and quality-control-Pass sensitivity analyses. In this cohort, a single measurement of an inflammation-focused protein panel showed limited discrimination between sepsis and sepsis mimics. Integration with clinical information and longitudinal measurements warrants further investigation.
]]></description>
<dc:creator><![CDATA[ Kasugai, D., Onizuka, H., Numaguchi, A., Yamamoto, T., Kato, N., Sumiyoshi, R., Fukui, S., Koga, T., Kawakami, A., Fujii, W., Kawahito, Y., Maruyama, S., Shimamura, T. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26365202</dc:identifier>
<dc:title><![CDATA[Inflammatory protein profiling shows limited ability to distinguish sepsis from sepsis mimics]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365120v1?rss=1">
<title>
<![CDATA[
Medicine carbon footprinting across National Health Service trusts in England, 2021-2024: a longitudinal study using Freedom of Information requests 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365120v1?rss=1
</link>
<description><![CDATA[
Introduction Medicines account for 20% of the National Health Service (NHS) carbon footprint, but it is unclear how consistently they are measured by individual NHS trusts. This study assessed medicine carbon footprint (MCF) practices across NHS trusts in England and whether these changed between 2021 and 2024. Methods Freedom of Information requests were sent to NHS trusts about MCF practices in 2021 and 2024. Responses were analysed to determine the proportion of trusts calculating MCFs, the medicines included and the emission factors used for spend-based calculations. Reported spend-based factors were compared with the median factor for each year to assess the effect of factor choice on MCFs. Results Of 196 trusts included in analysis, 178 (91%) responded for 2021 and 182 (93%) for 2024. Among responding trusts, 30 of 178 calculated MCFs in 2021 compared with 46 of 182 in 2024. Spend-based medicine footprinting increased from 19 trusts in 2021 to 31 in 2024. Ten different factors were used by 15 trusts in 2021 and 13 by 21 trusts in 2024. Reported factors ranged from 31% below to 258% above the median in 2024. Conclusions Medicine carbon footprinting remained uncommon, with only one-quarter of responding NHS trusts calculating a footprint in 2024. Among trusts using spend-based methods, wide variation in emission factors produced substantially different estimated MCFs. Clear national guidance on spend-based methodology could improve consistency in the short term, while greater use of standardised product-level approaches may better support medicine decarbonisation over time.
]]></description>
<dc:creator><![CDATA[ Taylor, H., Rahman, N. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365120</dc:identifier>
<dc:title><![CDATA[Medicine carbon footprinting across National Health Service trusts in England, 2021-2024: a longitudinal study using Freedom of Information requests]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365165v1?rss=1">
<title>
<![CDATA[
AI chatbots abandon sleep apnoea referral when simulated patients minimise symptoms 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365165v1?rss=1
</link>
<description><![CDATA[
Background: Patients increasingly consult free artificial intelligence (AI) chatbots about their symptoms, but these models may favour agreement with the patient over accuracy. In obstructive sleep apnoea (OSA), where most cases in the general population remain undiagnosed and diagnosis depends on referral, this could validate symptom denial. We tested whether consumer chatbots maintain guideline-concordant referral when a simulated patient minimises symptoms. Methods: Seven guideline-concordant and standardised OSA vignettes (apnoea-hypopnoea-index, AHI 8-52 events/h; body mass index 28-42 kg/m2) were presented to five free chatbots (GPT-5, Gemini 2.5 Flash, Claude Sonnet 4.6, DeepSeek V4 Flash and Grok-4.3) under neutral and symptom-minimising conditions (10 simulated conversations per model-vignette-condition cell; N=700). Referral maintenance was scored by a structured rubric and every capitulation was human-confirmed. Results: All chatbots maintained referral recommendations in neutral conversations (350/350; 100%). When simulated patients minimised symptoms and resisted referral, maintenance fell to 64.3% (225/350), a reduction of 35.7 percentage points (95% CI 5.5-66.0; p=0.028). Rates ranged from 55.7% to 85.7% across chatbots, but evidence of between-chatbot differences was inconsistent across analyses. Rates differed across clinical vignettes (p=0.001). A variance analysis estimated greater variation between vignettes than between chatbots. In the three driving-risk vignettes, referral recommendations were abandoned in 46-68% of symptom-minimising conversations, pooling all five chatbots within each vignette. Conclusions: Consumer AI chatbots abandoned correct OSA referral recommendations in about one-third of symptom-minimising conversations, with higher observed abandonment in simulated cases involving driving risk. This may delay appropriate assessment and raises patient- and public-safety concerns.
]]></description>
<dc:creator><![CDATA[ Ratneswaran, D., Poirier, S., Hamman, D., Rykov, M., Steier, J. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365165</dc:identifier>
<dc:title><![CDATA[AI chatbots abandon sleep apnoea referral when simulated patients minimise symptoms]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26365209v1?rss=1">
<title>
<![CDATA[
Longitudinal Pain Profiles and Their Clinical and Genetic Correlates in 624,996 U.S. Veterans 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26365209v1?rss=1
</link>
<description><![CDATA[
Importance: Pain varies in its intensity and course, yet much of our understanding of pain is based on cross-sectional assessments or longitudinal studies of selected clinical populations. Routinely collected electronic health record data may enable characterization of longitudinal pain patterns at scale. Objective: To identify longitudinal pain profiles among U.S. Veterans and characterize their clinical and polygenic correlates. Design: Cohort study using electronic health record and genomic data from the Million Veteran Program, with up to 16 years of pain assessments collected between 2000 to 2025. Setting: U.S. Department of Veterans Affairs health care system. Participants: Million Veteran Program participants assigned to African-like, Admixed American-like, East Asian-like, European-like, or South Asian-like genetically inferred ancestry groups who have at least three years of outpatient numeric rating scale pain records. Exposures: Outpatient pain ratings and polygenic scores for psychiatric, sleep, and substance use traits. Main Outcomes and Measures: Pain profiles were identified using Gaussian finite mixture modeling of pain intensity, directional change, and within-person variability. Profiles were characterized by pain, psychiatric and substance use diagnoses, opioid exposure, body mass index, and polygenic scores. Results: Among 624,996 participants (Mean [SD] age at first pain rating=53.4 [13.5] years; 568,833 [91.0%] male), 51,731,567 outpatient pain ratings were analyzed. Three profiles were identified: stable no pain, stable mild pain, and mild-to-moderate increasing pain. Compared with the stable no pain profile, the increasing pain profile had higher odds of chronic pain (OR=21.14 [95% CI: 18.96-23.57]), opioid use disorder (OR=9.32 [95% CI: 8.31-10.45]), opioid exposure (OR=8.61 [95% CI: 8.41-8.83]), major depressive disorder (OR=3.77 [95% CI: 3.67-3.87]), and posttraumatic stress disorder (OR=3.72 [95% CI: 3.61-3.84]). Associations were attenuated but remained after adjustment for mean pain severity. Polygenic scores for depression, insomnia, attention-deficit/hyperactivity disorder, and tobacco use disorder were the most consistent predictors of increasing pain across the three largest genetically inferred ancestry groups. Conclusions and Relevance: Longitudinal modeling of routinely collected pain scores identified pain profiles associated with clinical burden and polygenic liability. These profiles captured clinically meaningful information beyond mean pain severity alone, highlighting the value of longitudinal pain phenotyping in electronic health record data.
]]></description>
<dc:creator><![CDATA[ Davis, C. N., Shi, M., Gunawan, T., Toikumo, S., Million Veteran Program,, Gray, J., Kranzler, H. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26365209</dc:identifier>
<dc:title><![CDATA[Longitudinal Pain Profiles and Their Clinical and Genetic Correlates in 624,996 U.S. Veterans]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26364958v1?rss=1">
<title>
<![CDATA[
Methylation-defined tumour subgroups guide recognition of genetic predisposition in Wilms tumour 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26364958v1?rss=1
</link>
<description><![CDATA[
Up to one-third of Wilms tumours (WTs) arise in the context of genetic or epigenetic predisposition, but identifying predisposed patients remains challenging because germline variants can be missed due to variable clinical presentation, mosaicism, and cryptic variants. We tested whether tumour-derived molecular patterns can reveal underlying predisposition and thereby complement conventional diagnostic approaches. DNA methylation profiling of 138 WTs identified five molecular clusters that captured biological and predisposition-associated heterogeneity, including enrichment for Beckwith-Wiedemann Spectrum tumours, and a distinct WT1-driven subgroup. Cluster-guided reanalysis uncovered previously unrecognised WT1 pathogenic variants, including a newly identified germline variant that led to surveillance enrolment. A random forest classifier predicted WT1-driven tumours with ~90% accuracy across independent validation cohorts. Tumour methylation profiling identifies biologically and clinically relevant WT subgroups and reliably detects a WT1-driven tumour methylation signature. This approach can guide targeted variant reanalysis, and uncover clinically relevant germline variants missed by standard diagnostic workflows.
]]></description>
<dc:creator><![CDATA[ Oberhammer, F., van Peer, S. E., Buter, N. B., van Dijk, F., de Krijger, R. R., Bakhuizen, J. J., Bladergroen, R. S., van Grotel, M., Jongmans, M. C., van den Heuvel-Eibrink, M. M., Kester, L. A., Kuiper, R. P. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26364958</dc:identifier>
<dc:title><![CDATA[Methylation-defined tumour subgroups guide recognition of genetic predisposition in Wilms tumour]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26365226v1?rss=1">
<title>
<![CDATA[
FORESEE: A prospective feasibility trial of functional precision oncology for metastatic breast cancer patients 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26365226v1?rss=1
</link>
<description><![CDATA[
The FORESEE trial (NCT04450706) was a prospective study to evaluate the feasibility of integrating organoid-based drug testing with comprehensive genomic characterization to inform treatment selection in patients with HER2-negative metastatic breast cancer. The primary objective of the study was to determine the feasibility of providing personalized therapy recommendations using a combination of genomic vulnerability information with drug testing in patient-derived organoids (PDOs) in a clinically relevant time frame. Of the 15 patients enrolled, 10 cases had biopsies with adequate tumor content, and PDOs were successfully established in 4 of 10 cases. Drug profiling and genomic testing was completed in all established organoids, yielding an overall success rate of 40% in cases of biopsies with adequate tumor content. Drug sensitivity and genomic results were returned within 12 weeks and informed subsequent treatment selection in all evaluable cases. The primary endpoint - demonstrating that PDO-based drug screening combined with genomic characterization would identify clinically actionable outcomes in at least 46% of patients based on prior data - was not met. In conclusion, successful PDO establishment represents a limiting step in the implementation of FPO for metastatic breast cancer; however when PDO were successful, drug responses were always obtained and physicians chose to use the information in 100% of cases. These findings highlight the need for improved strategies optimizing use of patient biopsy material for drug testing in order to fully realize the clinical potential of FPO.
]]></description>
<dc:creator><![CDATA[ Vaklavas, C., Buys, S. S., Scherer, S. D., Kelley, K., Zhou, L., Yang, C.-H., Cortes-Sanchez, E., Butterfield, A., Huang, X., Moos, P. J., Qiao, Y., Reed, J., Boucher, K. M., Marth, G., Welm, B. E., Welm, A. L. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26365226</dc:identifier>
<dc:title><![CDATA[FORESEE: A prospective feasibility trial of functional precision oncology for metastatic breast cancer patients]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26364870v1?rss=1">
<title>
<![CDATA[
Source-water salinity measured by electrical conductivity in Bangladesh, 2025: a nationally representative cross-sectional survey 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26364870v1?rss=1
</link>
<description><![CDATA[
Background: In coastal Bangladesh, saline drinking water has been linked to raised blood pressure. The 2025 Multiple Indicator Cluster Survey (MICS) measured electrical conductivity (EC), a salinity indicator, in source water, but its report gave no population counts or district estimates. Objectives: To estimate how many people live in households whose tested source has high EC, and to describe patterns by place, household characteristics, source type and arsenic. Methods. EC was measured in source water of 6,040 households in 64 districts, February to June. In 14.5% of households the tested source was not the main drinking-water source. Primary outcomes were EC above 1,500 and 3,000 microsiemen/cm, survey risk classes that are not health-based standards. Estimates were survey weighted; comparisons were observational. Results: EC exceeded 1,500 microsiemen/cm in 5.3% of households (95% CI 4.7 to 5.9), about 9.0 million people, including 1.8 million above 3,000 microsiemen/cm. Coastal-zone districts held 26% of households but 70% of those above 1,500 microsiemen/cm. Shares varied little by wealth or in households with young children or pregnant women. Nationally, deep tube wells more often had high EC because most are coastal. In the coastal zone, deep and shallow wells had similar shares (16.1% and 17.9%). After district adjustment, EC was about 18% lower in deep wells (geometric mean ratio 0.82, 0.73 to 0.92). Within upazilas (restricted sample) it was 0.93 (0.80 to 1.07). Arsenic above 10 ppb was more common where EC was high, but this link weakened after district adjustment. Conclusions: Millions of people live in households whose tested source has high EC, mostly in coastal and south-central districts. Deep wells had modestly lower EC after geographic adjustment, but the difference shrank within upazilas and depended on the handling of implausibly low readings. The findings support measuring EC alongside arsenic, with documented meter calibration.
]]></description>
<dc:creator><![CDATA[ Hoque, S. M. A. U., Islam, M. K., Hasan, M. K., Rahman, M. A., Quaish, S. M., Banu, B., Hossain, Z. Z., Baset, K. u. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26364870</dc:identifier>
<dc:title><![CDATA[Source-water salinity measured by electrical conductivity in Bangladesh, 2025: a nationally representative cross-sectional survey]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26365211v1?rss=1">
<title>
<![CDATA[
Attenuated alpha state transitions and disrupted repetition-dependent temporal adaptation in mild cognitive impairment 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26365211v1?rss=1
</link>
<description><![CDATA[
Mild cognitive impairment (MCI) may involve impaired dynamic regulation of brain states that is not captured by conventional resting-state electroencephalography (EEG). We quantified occipital alpha (8-12 Hz) transitions during three repeated eye-opening/eye-closure cycles in 60 healthy controls (HC) and 77 participants with MCI. Eye-state events were refined from frontal ocular artifacts. Transition magnitude was measured by the log-transformed post-/pre-event energy ratio, and transition success by the expected direction of alpha change. For canonical transitions meeting prespecified fit-quality criteria, mono-exponential fitting yielded transition onset (t_onset) and the post-onset time constant (tau). MCI showed weaker alpha suppression during eye opening, weaker alpha enhancement during eye closure, and lower odds of transition success. No significant group difference in tau was detected within the canonical quality-controlled subset. In contrast, t_onset showed significant Group x Trial interactions in both conditions: HC developed later onset during eye opening and earlier onset during eye closure across repetitions, whereas MCI showed no comparable change. These findings suggest reduced alpha state-transition capacity and altered repetition-dependent temporal organization in MCI.
]]></description>
<dc:creator><![CDATA[ Wang, X., Zhu, Y., Zhang, J., zheng, z., Yu, M. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26365211</dc:identifier>
<dc:title><![CDATA[Attenuated alpha state transitions and disrupted repetition-dependent temporal adaptation in mild cognitive impairment]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365112v1?rss=1">
<title>
<![CDATA[
Stroke Care in Rural Kenya: The Gap Between Clinical Practice and Stroke Care Guidelines in Kiambu County, Kenya 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365112v1?rss=1
</link>
<description><![CDATA[
Background In Kenya, stroke is one of the top five causes of mortality, with a high rate of inpatient mortality. The American Heart Association (AHA) and American Stroke Association (ASA) translated scientific evidence into evidence-based clinical practice guidelines aimed at reducing inpatient mortality and improving the quality of care for stroke patients. Despite the proven benefits of the ASA stroke guidelines in improving stroke care, translation of the guidelines in various settings remains a key challenge. This study aimed to quantify the gap between evidence-based recommendations and current stroke care practices in a peri-urban referral facility in Kiambu, Kenya. The study was conducted at xxxxxxxxxx Hospital, a peri-urban referral facility in Kiambu County, Kenya. Methods: We reviewed records of stroke patients attending xxxxxxxxxxx from January 1, 2020, to December 31, 2023. The study evaluated acute stroke management practices and secondary prevention against the 2019 American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Acute Ischemic Stroke. Results: The median distance travelled by stroke patients to the facility was 47.8 kilometres; further, the median onset-to-presentation time was 24 hours. The study evaluated eight clinical practices against the ASA guidelines. The facility lacked a dedicated stroke unit. Remarkably, patients arriving within the therapeutic window for intravenous alteplase and thrombectomy did not receive these treatments. Secondary prevention measures, including discharge on an antiplatelet regimen, were moderately adhered to; among the 86 eligible ischemic stroke patients, 67 (77.9%) were correctly discharged on aspirin. Similarly, 84/123 (68.3%) of the patients were discharged on statin therapy. Conclusion: Evidence-based stroke care recommendations were minimally adhered to at this peri-urban referral facility in Kiambu, Kenya. Contribution: This study quantifies the gap between evidence-based stroke care recommendations and current clinical practice in a peri-urban referral facility in Kenya, providing context-specific evidence to inform quality improvement initiatives and guideline implementation efforts in similar resource-constrained settings.
]]></description>
<dc:creator><![CDATA[ Yulu, E., Ngesa, R. W., Gatimu, S., Waweru, P. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365112</dc:identifier>
<dc:title><![CDATA[Stroke Care in Rural Kenya: The Gap Between Clinical Practice and Stroke Care Guidelines in Kiambu County, Kenya]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26364862v1?rss=1">
<title>
<![CDATA[
Upper cervical spinal cord morphometric charts: from population references to individualized clinical assessment 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26364862v1?rss=1
</link>
<description><![CDATA[
The upper cervical spinal cord is essential for motor, sensory and autonomic function, yet its normative morphometric trajectories and disease-related deviations remain unclear. Using three-dimensional T1-weighted images from 10,159 healthy individuals aged 8-85 years, we established normative references for averaged and level-specific upper cervical spinal cord morphometry, revealing measure-specific trajectories with peak ages of 29.7-44.1 years. These references were applied to 2,394 patients with seven neurological disorders: mild cognitive impairment, Alzheimer' s disease, Parkinson' s disease, cerebral small vessel disease, multiple sclerosis, neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease to derive individualized deviation scores. These deviation scores captured disease-specific abnormalities, enabled disease classification, and were associated with cognition, physical disability and disease progression. Finally, a personalized upper cervical spinal cord report was developed to support individualized imaging interpretation. Together, these findings provide a normative framework for quantifying upper cervical spinal cord morphometry and advancing personalized assessment across neurological disorders.
]]></description>
<dc:creator><![CDATA[ Wang, J., Hua, T., Wu, H., Zhang, R., Xu, S., Zhang, C., Chai, L., Yao, Y., Gao, T., Bai, L., Du, X., Zhang, C., Lin, B., Liao, L., Wang, H., Luo, Y., Zhu, X., Deng, D., Wu, Y., Zhang, R., Zhang, Z., Zhou, F., Zhu, J., Zuo, X.-N., Cheng, S., Xia, X., Meng, X., Kong, Y.-Z., Cohen-Adad, J., Guo, R., Xia, S., Duan, Y., Zhuo, Z., Liu, Y., Chinese Brain Health Imaging Consortium (CHART) ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26364862</dc:identifier>
<dc:title><![CDATA[Upper cervical spinal cord morphometric charts: from population references to individualized clinical assessment]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365056v1?rss=1">
<title>
<![CDATA[
Computational modelling of decision-making in suicide attempters 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365056v1?rss=1
</link>
<description><![CDATA[
Importance. Suicide is a leading cause of mortality, yet its prevention remains a challenge. Suicide attempters exhibit disrupted decision-making, but the specific cognitive processes driving this impairment and their utility for risk stratification are unclear. Objective. To determine which computational decision-making mechanisms are disrupted in high-risk suicide attempters, and whether they distinguish attempters from depressed and healthy controls. Design. This cross-sectional study fit reinforcement-learning models to Iowa Gambling Task performance across two independent studies: SPAD (August 2017 to May 2020); SUICIDE-DECIDE (March 2021 to September 2023). Data was analyzed between January 2025 and July 2026. Setting. SPAD was conducted in Nimes (France). SUICIDE-DECIDE was a muticenter study across Jena (Germany) and Nimes. Clinical groups were recruited from academic inpatient psychiatry units and outpatient clinics, and healthy controls through local advertisement. Participants. SPAD included adults aged 60 years or older; SUICIDE-DECIDE middle-aged adults stratified by attempt means (violent/nonviolent). Consecutive participants were recruited into three groups: suicide attempters, patient controls, healthy controls. Main outcomes and measures. The primary outcomes were group differences on parameters reflecting learning from rewards and losses, sensitivity to win frequency, choice perseverance, and forgetting of past choices. We trained a multinomial logistic regression model in the SUICIDE-DECIDE study using self-reported depression and parameters that differentiated attempters from controls across studies, and evaluated its performance in the SPAD sample. Results. SPAD included 57 participants (40 females [70.2%]; mean [SD] age, 70.1 [8.2]). SUICIDE-DECIDE included 124 participants (77 females [62.1%]; 32.1 [11.0]). Suicide attempters forgot past choices faster than controls (SPAD: F(2,36) = 13.5; P < .001; SUICIDE-DECIDE: F(3,57) = 46.6; P < .001). No other parameter specifically differed in attempters across studies. In SUICIDE-DECIDE, greater forgetting of past choices was associated with attempter status only (RRR = 4.2, 95% CI [1.5, 11.5]). This parameter paired with depression severity correctly classified 87.2% of participants in SPAD (95% CI [74.3%, 95.2%], 41/47). Conclusions and relevance. Short-sighted decision-making may represent a cognitive phenotype associated with suicide in high-risk populations and a potential target for prevention and treatment.
]]></description>
<dc:creator><![CDATA[ Grande, C., De Zorzi, L., Abbar, M., Wagner, G., Jollant, F. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365056</dc:identifier>
<dc:title><![CDATA[Computational modelling of decision-making in suicide attempters]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365109v1?rss=1">
<title>
<![CDATA[
Efficacy of Repeated-Dose Albendazole/ Mebendazole Regimens for Soil-Transmitted Helminth Infections in Paediatric Population: A Systematic Review and Meta-Analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365109v1?rss=1
</link>
<description><![CDATA[
Background: Preventive chemotherapy via single-dose benzimidazoles remains the core strategy for soil-transmitted helminth (STH) control. However, single-dose regimens often yield sub-optimal clearance against species such as Trichuris trichiura and hookworm. This systematic review and meta-analysis evaluated the comparative efficacy of repeated-dose versus standard single-dose albendazole or mebendazole regimens in paediatric populations.  Methods: Registered prospectively on PROSPERO (CRD420261491616), a comprehensive search of PubMed, Embase, Cochrane Library, and Google Scholar identified clinical trials comparing repeated-dose against single-dose albendazole or mebendazole in paediatric STH infections. Primary outcomes were cure rate (CR) and egg reduction rate (ERR). Random-effects models synthesized pooled odds ratios (OR) and mean differences (MD). Risk of bias was assessed using the Cochrane RoB 2 tool.  Results: Five randomized clinical trials (N = 1,718 participants) met the inclusion criteria. Overall, repeated dosing demonstrated significant superiority in cure rate (pooled OR = 4.47, 95% CI: 1.58-12.67; I{superscript 2} = 92%) and egg reduction rate (pooled MD = 0.17, 95% CI: 0.01-0.32; I{superscript 2} = 87%). Discussion: Repeated-dose benzimidazole regimens offer superior overall therapeutic efficacy compared to standard single-dose administration in children. However, this therapeutic advantage is drug-specific: multi-dose albendazole consistently enhances parasite clearance across trial settings, whereas multi-dose mebendazole exhibits variable performance and lacks conclusive superiority over single dosing.  Conclusion: Transitioning to targeted, multi-dose albendazole protocols--rather than mebendazole--may serve as an effective public health intervention to eliminate residual parasite reservoirs in high-transmission endemic regions.
]]></description>
<dc:creator><![CDATA[ Singh, N., Sahu, P., Singh, V., Bharti, P. P., Siddiqui, A. M., Kumar, A. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365109</dc:identifier>
<dc:title><![CDATA[Efficacy of Repeated-Dose Albendazole/ Mebendazole Regimens for Soil-Transmitted Helminth Infections in Paediatric Population: A Systematic Review and Meta-Analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26364997v1?rss=1">
<title>
<![CDATA[
Dynamics of a slow-burn epidemic: the genomic epidemiology of poultry-associated Campylobacter jejuni ST474 in New Zealand 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26364997v1?rss=1
</link>
<description><![CDATA[
The emergence of a dominant poultry-associated strain of Campylobacter jejuni in New Zealand coincided with a multi-year epidemic of human campylobacteriosis. This was characterised by an increase in cases to 2006, when one of the highest national case-rates in the world was recorded, followed by a rapid decline attributed to interventions in the poultry industry. The strain belonged to an internationally rare multilocus sequence type, ST474 - a member of Clonal Complex (CC) 48 - that was highly prevalent in both poultry and human cases in New Zealand but was also identified in other samples. ST474 isolates from humans, animal reservoirs and environmental water samples were collected between 2005 and 2019 and whole genome sequenced (N=443). Isolates from a 2018/9 case-control study of campylobacteriosis in New Zealand were included for genomic comparisons with other sequence types and CCs. This presented an opportunity to examine the genomic epidemiology of a single, relatively recently emerged lineage of C. jejuni, and improve our understanding of drivers of emergence and persistence in a relatively isolated ecosystem. Six subpopulations (clades) of ST474 were identified and these varied in terms of their host association, persistence, patterns of homologous recombination, and complement of mobile genetic elements, including plasmids and chromosomally integrated elements. Clade E was associated with a single poultry supplier in the initial epidemic phase and accounted for 34.5% of human cases. Clade F emerged from a declining Clade E after the peak in human cases and was also associated with poultry. The emergence of Clade F was accompanied by the loss of integrated element CJIE5 and the acquisition of multiple blocks of recombination, likely from diverse ancestral C. jejuni lineages, and the loss of the methionine biosynthesis operon metAB. In contrast, Clades A-D were detected at low frequencies in human cases over the 14-year period of surveillance and were associated with multiple hosts. This longitudinal study sheds light on the evolutionary processes that result in strain emergence and differentiation, highlighting the role of horizontal gene transfer in the evolution and adaptation of this pathogen to new niches, and the subsequent impact on public health.
]]></description>
<dc:creator><![CDATA[ French, N. P., Wilkinson, D. A., Biggs, P. J., Midwinter, A. C., Collins-Emerson, J. M., Fayaz, A., Marshall, J. C., Muellner, P., Rogers, L. E., Parolin Calarga, A., Mather, A. E. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26364997</dc:identifier>
<dc:title><![CDATA[Dynamics of a slow-burn epidemic: the genomic epidemiology of poultry-associated Campylobacter jejuni ST474 in New Zealand]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365189v1?rss=1">
<title>
<![CDATA[
EpiAlert: A Transparent CUSUM-EWMA Framework for Early Warning of Unusual Influenza-Like Illness Surveillance Activity 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365189v1?rss=1
</link>
<description><![CDATA[
Automated surveillance systems can prove to be extremely useful in detecting outbreaks of respiratory diseases that need further epidemiological investigation. In order for the system to be effective, careful attention has to be paid to the baseline used, absence of the observations, and the use of proper statistical methods. As a solution, the paper describes EpiAlert, a weekly surveillance system based on CDC FluView ILINet. The system is able to transform the number of ILI visits and the total number of visits into a ILI prevalence for the region, create the first reference from the three previous years using a +/- 2-week interval, transform the rate value, and apply two different detectors - CUSUM and EWMA. CUSUM is set at k=0.5 and h=5, whereas EWMA uses {lambda}=0.2 and H=2.7 values. Among the 55 districts, the system gives 45,138 pieces of information about the disease by transforming 44,297 pieces of data into alerts. It is found that there are 2,820 alerts in total (out of which 2,711 alerts used CUSUM, 402 used EWMA, and 293 used both detectors). Additionally, the experiments show that the sensitivity of the device depends greatly on the detector. The latest statistics can be tracked in the report for week 37 of 2026 that recently concluded in West.
]]></description>
<dc:creator><![CDATA[ Reddy, V., Reddy, S. V., Ram, V., K, N. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365189</dc:identifier>
<dc:title><![CDATA[EpiAlert: A Transparent CUSUM-EWMA Framework for Early Warning of Unusual Influenza-Like Illness Surveillance Activity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365176v1?rss=1">
<title>
<![CDATA[
Does handgrip strength improve cardiometabolic risk stratification beyond detailed body composition? NHANES 2011-2014 with temporal validation 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365176v1?rss=1
</link>
<description><![CDATA[
Background: Handgrip strength is associated with cardiometabolic abnormalities, but whether it adds information once detailed adiposity and muscle mass are known is unclear. Methods: We studied adults aged 40-59 years from NHANES 2011-2012 (development, n=508) and 2013-2014 (temporal validation, n=616). The outcome was at least two of four non-adiposity abnormalities (elevated blood pressure, fasting glucose or triglycerides, or low HDL cholesterol); waist circumference was not part of the outcome. A prespecified feature ladder added DXA body fat percentage and visceral adipose tissue to age, sex, BMI and waist circumference (M1), then appendicular skeletal muscle index (M2), then absolute (M3A, primary) or weight-normalised (M3B) grip strength. Logistic regression was primary; elastic-net and XGBoost were supportive. Development performance used nested cross-validation; frozen models were scored once in the validation cohort. Paired increments used 2000 stratified bootstrap resamples. Results: The outcome occurred in 249 (49.0%) and 277 (45.0%) participants. Adding adiposity increased the logistic regression AUC by 0.0209 (95% CI 0.0024-0.0402) in development and 0.0209 (0.0032-0.0375) in temporal validation. Adding absolute grip strength to M2 changed the AUC by -0.0046 (-0.0107 to 0.0013) and 0.0045 (-0.0009 to 0.0098), respectively. All 12 grip-strength AUC increments across algorithms, definitions and cohorts had intervals that included zero. Calibration was unchanged and the incremental net benefit was not consistently positive. Model attributions to grip strength varied by algorithm. Conclusions: In middle-aged adults, detailed adiposity, but not grip strength, added reproducible information for concurrent cardiometabolic risk stratification beyond conventional anthropometry and muscle mass.
]]></description>
<dc:creator><![CDATA[ Zhan, X., Shen, M., Zhang, Y., Mao, X. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365176</dc:identifier>
<dc:title><![CDATA[Does handgrip strength improve cardiometabolic risk stratification beyond detailed body composition? NHANES 2011-2014 with temporal validation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365170v1?rss=1">
<title>
<![CDATA[
Ascending Aortic Calcium Identifies Patients at Risk Despite Normal Myocardial Flow, Perfusion and Coronary Calcium: A 13-Site Cohort Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365170v1?rss=1
</link>
<description><![CDATA[
Background Patients with normal perfusion, normal myocardial flow reserve (MFR) and no coronary artery calcium (CAC) on myocardial perfusion imaging are considered low risk. Yet, adverse events still occur and no routinely reported imaging marker stratifies residual risk. This study aims to determine whether fully automated ascending aortic calcification (AAC) from the attenuation correction CT stratifies risk in these patients. Methods In the multicenter REFINE-PET registry, AAC was quantified from non-contrast CT using deep learning aortic segmentation and Agatston scoring. Triple-normal was defined as stress total perfusion deficit (TPD) <5%, MFR >2 and CAC 0. The primary endpoint was cardiovascular death, myocardial infarction or heart failure admission, with heart failure admission as key secondary endpoint. Cox models were adjusted for clinical confounders. Results Of 21,923 patients, 3,580 (16.3%) were triple-normal, of whom 1,322 (36.9%) had AAC (median Agatston 65, IQR 22-212). Agreement with three blinded readers was good to excellent (Intraclass correlation coefficient 0.87-0.90). Over a median follow-up of 52 months (IQR 26-69), 194 primary events occurred. Per standard deviation, AAC was independently associated with the primary endpoint (adjusted HR 1.24, 95% CI 1.09-1.40; p<0.001), heart failure admission (adjusted HR 1.30, 95% CI 1.10-1.55; p=0.003) and all-cause mortality (adjusted HR 1.17, 95% CI 1.04-1.32; p=0.009). AAC improved model fit beyond clinical factors, MFR and TPD (p< or =0.009), with modest gains in discrimination ({Delta}C 0.007-0.009). Conclusions In patients with normal PET readouts, automated AAC was independently associated with adverse outcomes, most strongly heart failure admission, beyond clinical risk factors, perfusion and flow.
]]></description>
<dc:creator><![CDATA[ Spielvogel, C., Shanbhag, A., Khanna, S., Zuhair Kassem, T., Lemley, M., Yi, J., Ramirez, G., Kavanagh, P., Kamagate, A., Slipczuk, L., Travin, M. I., Buechel, R. R., DeKemp, R. A., Alexanderson, E., Carvajal-Juarez, I., Packard, R. R., Al-Mallah, M., Einstein, A. J., Acampa, W., Knight, S., Le, V. T., Mason, S., Rosamond, T. L., Miller, R. J., Chareonthaitawee, P., Dey, D., Berman, D. S., Di Carli, M. F., Slomka, P. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365170</dc:identifier>
<dc:title><![CDATA[Ascending Aortic Calcium Identifies Patients at Risk Despite Normal Myocardial Flow, Perfusion and Coronary Calcium: A 13-Site Cohort Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365115v1?rss=1">
<title>
<![CDATA[
Population-scale trends and variations in human aortic biomechanics 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365115v1?rss=1
</link>
<description><![CDATA[
The biomechanical properties of the human aorta play a key role in cardiovascular function and disease, yet their population-wide trends and variations remain largely unknown. To fill this crucial gap, we quantified variations in aortic size, stiffness and stresses across 57,434 individuals from the UK Biobank using two-dimensional cine MR imaging and a combined deep-learning, probabilistic and biomechanical modelling framework. Aortic diameter and distensibility (inverse of stiffness) were calculated for the ascending and descending aorta, and their conditional distributions were characterised as a function of age, sex, body size and blood pressure. These observations were integrated with ex-vivo tissue mechanics to infer stress distributions across the aortic wall and the associated uncertainty. Our analysis revealed several new relationships. Larger aortas were found to be stiffer, and greater body size (height and/or weight) was associated with larger aortas with no change in stiffness. Aortic distensibility was negatively associated with systolic, but not diastolic, blood pressure. Apparent sex differences in aortic size were substantially reduced after accounting for body size. Importantly, the maximum stress was found to depend not only on aortic size, as previously thought, but also on distensibility, with lower distensibility associated with higher stresses. The results provide first-of-their-kind population-scale reference distributions for human aortic stiffness, which will improve the personalisation of computational models and digital twins. The correlation between stress and distensibility strongly supports progressing beyond the current diameter-based criteria (based on the law of Laplace) and for the inclusion of stiffness in the clinical risk assessment of aortic diseases. Overall, this study forms the foundation for personalised quantitative medicine and biomechanically informed risk stratification of aortic aneurysms and dissections.
]]></description>
<dc:creator><![CDATA[ Aggarwal, A., Byun, J.-E., Capelli, C., Danton, M., Famaey, N., McBride, A., Pouch, A., Schievano, S. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365115</dc:identifier>
<dc:title><![CDATA[Population-scale trends and variations in human aortic biomechanics]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365178v1?rss=1">
<title>
<![CDATA[
30-Day Heart Failure Readmission and Post-Discharge Healthcare Use Among Older Australians: A Linked-Data Mixed-Methods Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365178v1?rss=1
</link>
<description><![CDATA[
Abstract Background: Heart failure (HF) is a major public health challenge in ageing populations and a leading cause of unplanned hospital readmissions. Biological, social, and economic factors contribute to recurrent hospitalisation, but gaps remain in understanding how these factors interact and patterns of healthcare use following hospitalisation. Methods: We conducted an explanatory sequential mixed-methods study of patients aged ?60 years with an HF hospital admission between 2016 and 2020 who completed the Sax Institute?s 45 and Up Study baseline questionnaire. Data were linked to Admitted Patient Data Collection, Medicare Benefits Schedule, and Pharmaceutical Benefits Scheme data. HF readmission within 30 days of the index admission was the outcome. Cox proportional hazards models estimated crude and adjusted hazard ratios (HRs and adjHRs) with 95% confidence intervals (CIs). Kaplan-Meier curves and log-rank tests compared survival between groups. Time-series plots mapped healthcare interactions over 1 year following the index admission. Results: Among 4,252 patients with HF, 409 were readmitted within 30 days. Significant predictors included age ?80 years (adjHR, 1.30; 95%CI, 1.01?1.67), 1 chronic condition (adjHR, 2.49; 95%CI, 1.41?4.40), ?2 chronic conditions (adjHR, 1.75; 95%CI, 1.04?2.95), and alcohol consumption above national guidelines (adjHR, 1.45; 95%CI, 1.06?1.98). Time-series analysis indicated that participants with readmission had more frequent out-of-hospital health service contact following their initial HF admission than those without readmission. Conclusions: Older age, chronic conditions, and high alcohol intake increased 30-day HF readmission risk. Differences in healthcare use after admission highlight opportunities for targeted and coordinated post-discharge care.
]]></description>
<dc:creator><![CDATA[ Leong, C. S., Kabir, A., Barr, M. L. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365178</dc:identifier>
<dc:title><![CDATA[30-Day Heart Failure Readmission and Post-Discharge Healthcare Use Among Older Australians: A Linked-Data Mixed-Methods Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365132v1?rss=1">
<title>
<![CDATA[
Real-time wearable detection of respiratory infections in pediatric transplant households 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365132v1?rss=1
</link>
<description><![CDATA[
Consumer-grade wearables can continuously and longitudinally measure health signals such as heart rate (HR), activity, and sleep. While changes in these signals have been implicated in the early detection of infection (e.g., influenza, SARS-CoV-2) and real-time alerting systems have been developed, evidence from prospective deployment in pediatric transplant households remains limited. Here, we study the application of a resting heart rate (RHR)-based real-time alerting algorithm to detect respiratory virus infection in a cohort of solid organ transplant recipients and their household members (n=146) in a Phase IV clinical trial (NCT06161454). Reliable and efficient alerting for infection events may be particularly relevant for this population, enabling isolation, clinical management, and/or treatment. Of 31 antigen-test outcomes, nearly all (29/31, 93.5%) correspond to either influenza, COVID, or other patient-reported symptoms. We describe RHR, HR, activity, and sleep/circadian rhythm features around clinical alarm events, identifying candidate features for further investigation and algorithm improvement.
]]></description>
<dc:creator><![CDATA[ Mayer, C., Hurwitz, E., Bhatia, T., Chung, A., Gandla, D., Domenick, B., Rasanen, E., Nair, N., Rangan, E. S., Ahmed, H., Brathwaite, C., Arcila-Meso, M., Gao, H., Verrou, K.-M., Mauduit, V., Parenti, M. B., Rand, E., Shah, A. A., Myhrvold, C., Wang, C., Amaral, S., O'Connor, M. J., Snyder, M. P., Keating, B. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365132</dc:identifier>
<dc:title><![CDATA[Real-time wearable detection of respiratory infections in pediatric transplant households]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.09.26365168v1?rss=1">
<title>
<![CDATA[
Effectiveness of a mHealth nutrition and lifestyle intervention (mHENAL) in reducing Cardiovascular Disease Risk in Sri Lankan adults: A Randomized Control Trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.09.26365168v1?rss=1
</link>
<description><![CDATA[
Cardiovascular diseases (CVD) are the leading cause of global mortality, responsible for 17.8 million deaths and 423 million prevalent cases annually. While the etiology of CVD is multifactorial, evidence confirms that multicomponent behavioral interventions regarding diet and lifestyle can substantially reduce risk. This study aimed to evaluate the effectiveness of a 12-month mHealth intervention, i.e., public health practice supported by mobile devices in reducing the 10-year CVD risk among overweight and obese adults aged 35 to 64 in an urban Sri Lankan population. A two-group parallel-arm randomized control trial (RCT) was conducted with 1,200 participants from the Colombo district, assigned either to an intervention arm (n=600) or a usual care control arm (n=600). The intervention group received automated text and voice messages in their native language at a frequency of two of each per week over 12 months. The primary outcome, 10-year CVD risk, was assessed using the WHO CVD risk prediction score. The intervention significantly reduced the proportion of participants with a 10-year CVD risk from 10.0% to 6.2% (p=0.003), whereas no significant change was observed in the control group (11.0% to 9.7%). Participants in the mHealth arm demonstrated substantial behavioral improvements, including increasing daily fruit and vegetable servings from 3.6 to 5.5 and reducing daily salt intake from 7.64g to 5.62g. Physical activity levels also improved, with 89.6% meeting minimum daily requirements compared to 77.4% at baseline. These findings suggest a potentially beneficial effect on predicted cardiovascular risk. The study concludes that an automated mHealth intervention is an effective, feasible, and acceptable approach to reducing cardiovascular risk in an urban South Asian setting. The findings provide a robust evidence base for integrating digital health strategies into national non-communicable disease (NCD) prevention policies. While the 12-month results are promising, further longitudinal research is required to evaluate the long-term sustainability of these behavioral changes and their ultimate impact on mortality rates.
]]></description>
<dc:creator><![CDATA[ Senarath, U., Katulanda, P., Kalupahana, N. S., Partheepan, K., Dibley, M. J. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.09.26365168</dc:identifier>
<dc:title><![CDATA[Effectiveness of a mHealth nutrition and lifestyle intervention (mHENAL) in reducing Cardiovascular Disease Risk in Sri Lankan adults: A Randomized Control Trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.10.10.26364993v1?rss=1">
<title>
<![CDATA[
Estimating Physician-Patient Face-to-Face Time Using Electronic Health Record Audit Logs 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.10.10.26364993v1?rss=1
</link>
<description><![CDATA[
Importance: The Medicare Physician Fee Schedule values ambulatory services using survey-based estimates of physician time, a costly process vulnerable to inaccuracy. EHR audit logs are passively and universally collected and likely meet the American Medical Association Relative Value Scale Update Committee (AMA RUC) Extant Database Standards for alternative data to inform service valuation estimates. However, audit logs' validity for estimating face-to-face time, a core component of many of the most used procedural codes, is unknown. Objective: To assess whether EHR audit logs can facilitate accurate estimation of physician-patient face-to-face time during ambulatory visits. Design: Single-site validation study pairing EHR audit logs with direct audio/video recordings of ambulatory primary care visits (reference standard). We assessed agreement between audit-log estimates and recorded visit duration with Bland-Altman analysis and mean absolute error. Setting: University of Pennsylvania Observer data repository, a multi-modal database of ambulatory visits to Penn Medicine primary care clinics including video and audio recordings, transcripts, clinical EHR data, and EHR audit-log data. Participants: 75 visits from 12 physicians with data collected between August 2023 and February 2025. Exposures: A rule-based algorithm estimated face-to-face time via clusters of physician EHR activity relative to patient check-in time. Inactivity thresholds were applied to differentiate intraservice time with no EHR activity (e.g., a physical exam) from the end of a visit, with longer thresholds used for longer visits. Main Outcomes and Measures: Duration of recorded face-to-face visit time. Results: Recorded face-to-face time averaged 31.6 minutes (SD, 13.9). The audit-log estimator was unbiased (mean bias: -0.63 minutes; 95% CI: -6.0 to 2.6; mean absolute error: 9.0 minutes) and estimated face-to-face time within approximately 2% (38 seconds) of the recorded visit time with no proportional bias (slope: 0.13; P = .25). The 95% limits of agreement were -25.7 to 24.4 minutes, and 37% of estimates fell within 10% of recorded duration. Conclusions and Relevance: In this validation study, EHR audit logs recovered unbiased estimates of ambulatory face-to-face time. Larger-scale studies are required to verify generalizability, but EHR audit logs offer a scalable means to improve the rigor of retrospective physician work relative value unit estimation. This study represents a first step in a potential paradigm shift for measuring components of the fee schedule across procedures, settings, and provider types.
]]></description>
<dc:creator><![CDATA[ Apathy, N. C., Cross, D. A. ]]></dc:creator>
<dc:date>2026-10-12</dc:date>
<dc:identifier>doi:10.64898/2026.10.10.26364993</dc:identifier>
<dc:title><![CDATA[Estimating Physician-Patient Face-to-Face Time Using Electronic Health Record Audit Logs]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-10-12</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
